Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger FYVE domain-containing protein 9 (ZFYVE9) is an early endosomal adapter protein known for its role as a scaffold in the transforming growth factor-beta (TGF-beta) signaling pathway. It functions by recruiting SMAD2/3 proteins to the TGF-beta receptor complex at the endosomal membrane, facilitating their phosphorylation and subsequent nuclear translocation, which is essential for TGF-beta–mediated transcriptional responses. ZFYVE9/SARA contains a FYVE-type zinc finger domain that targets it to endosomal membranes by recognizing phosphatidylinositol 3-phosphate. It influences several cellular processes through SMAD signaling, including cell growth, differentiation, and development. Dysregulation of ZFYVE9 or its pathway partners can contribute to certain pathologies, such as cancer and immune-mediated glomerulonephritis[1][3][6][9][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger FYVE domain-containing protein 9 (ZFYVE9).